Globus Medical (GMED) Common Equity (2011 - 2026)

Globus Medical (GMED) has reported Common Equity for 16 consecutive years, with $4.8 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 11.01% year-over-year to $4.8 billion; the trailing twelve-month figure through Jun 2026 stood at $4.8 billion (up 11.01% YoY), and the FY2025 full-year result was $4.6 billion, up 9.48% from the prior year.
• Common Equity rose to $4.8 billion in Q2 2026 per GMED's latest filing, from $4.7 billion in the prior quarter.
• Across five years, Common Equity topped out at $4.8 billion in Q2 2026 and bottomed at $1.7 billion in Q2 2022.
• Historically, Common Equity has averaged $3.5 billion across 5 years, with a median of $4.0 billion in 2023.
• The sharpest annual moves came in 2023 and 2024: Common Equity soared 137.36% in 2023, then decreased 2.82% in 2024.
• Over 5 years, Common Equity stood at $1.8 billion in 2022, then soared by 116.53% to $4.0 billion in 2023, then gained by 4.49% to $4.2 billion in 2024, then gained by 9.48% to $4.6 billion in 2025, then gained by 4.27% to $4.8 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $4.8 billion, $4.7 billion, and $4.6 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.